Acorda Therapeutics, Inc., along with its affiliates, filed its first amended joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on July 1, 2024. As per the amended plan filed, Prepetition Notes Secured Claims of $171.14 million shall be recovered 63% i.e., $107.82 million of its pro rata share in cash. General Unsecured Claims of $11.4 million shall be recovered 1% i.e., $0.11 million of its pro rata share in cash.

Other Secured Claims, Other Priority Claims, Biotie Claims, Intercompany Claims, and Subordinated Claims are of $0. There are no changes in treatment of any other claim class or sources of plan funding. Acorda Therapeutics, Inc., along with its affiliates, filed a solicitation version of its first amended joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on July 2, 2024. As per the amended plan filed, there are no changes in treatment of any claim class or sources of plan funding.